Nandhu et al. developed an antibody against fibulin-3 called mAb428.2, which is able to prevent the fibulin-3-activation of ADAM17, resulting in cell apoptosis, enhancement of inflammatory macrophage infiltration, reduced tumor growth and vascularization, and extended survival in Glioblastoma mouse models [167]. Here, EFEMP1 is linked to neoplasm.